PharmaTelevision - Hybrigenics: William Vickery talks about their focus on research and development of new cancer treatments, including prostate cancer.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Hybrigenics: William Vickery talks about their focus on research and development of new cancer treatments, including prostate cancer.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to William Vickery, Head of Corporate and Business Development at Hybrigenics

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Hybrigenics's dual business model

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe Duesseldurf, Germany. On this show I have William Vickery, who is Head of Corporate and Business Development at a company called Hybrigenics based in Paris, welcome to the show.

William Vickery:

Hello Fintan, glad to be here.

Fintan Walton:

So Hybrigenics is a publically listed company you can tell us a little bit about that, but also you've got a dual-business model, you've got a pharma side or a drug development side and you've also got a services side, so first of all give us a little bit of the history of Hybrigenics?

William Vickery:

It's great, Hybrigenics was created in 1998 out of technology that was brought by our founders to look at protein interaction and we did our IPO in 2007 we are listed on Alternext now with a market capital of about 16 million Euros and as you correctly described we do have a dual business model, we have pharma activity with development we are developing a vitamin D receptor agonist called Inecalcitol which we are developing for prostate cancer and for psoriasis, we also have a services activity, sorry on the pharma side let me come back to that, we also had some research activity where we are looking at deubiquitinating enzymes focusing on ubiquitin-specific proteases which are sub family of deubiquitinating enzymes we've got some world class research taking place there which recently lead to a deal with Servier. And then on the services side we are working on protein interaction activities enabling pharmaceutical, healthcare, life science companies so very broad range of companies as well as academics to identify protein interactions when they got a protein of interest and that works for things like the agri business as well as the cosmetics industry and the pharmaceutical industry.

Fintan Walton:

Right, so obviously the service side gives you cash flow coming through the business and obviously doing research you have to consume cash?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

William Vickery

Head of Corporate and Business development

At the time of recording this PTV interview William Vickery serves as Head of Corporate and Business Development at Hybrigenics. William joined Hybrigenics in 2010. William works in "business development" in the pharmaceutical industry since 2001, both in the biotech (ExonHit in Paris) in a large pharmaceutical company (Hoffmann La Roche, Switzerland and the USA). During this time he worked on a variety of partnerships and licensing agreements between biotech companies and medium and large academic centers as well. A ExonHit he also led the project team that conducted the Phase 2a study of EHT 0202 (candidate drug against Alzheimer's disease). William holds an MBA from INSEAD and an engineering school of Advanced Studies in Engineering (HEI) in Lille.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Hybrigenics

Founded in 1997, Hybrigenics is a biopharmaceutical company focusing its research and development programs on innovative targets and therapies against proliferative diseases, cancer or non-cancerous. Hybrigenics also markets in the form of scientific services to its broadband technology platform able to identify, validate and inhibit protein interactions. The development program for the most advanced Hybrigenics based on inecalcitol, a vitamin D analogue, tested in two directions: - the prostate cancer in combination with current standard of care, with the aim of improving the efficacy and safety. - moderate to severe psoriasis. The research program Hybrigenics explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the proprietary USP inhibitors in various types of cancer . In addition, Hybrigenics provides researchers of all sectors of life sciences a range of services so as to implementing the screening platform yeast two-hybrid ( Y2H ) ISO 9001 certified, tools bioinformatics sophisticated, its database of interactions between proteins and its chemicallibrary and chemical screening platform at high speed. Hybrigenics is organized into two business units: Hybrigenics Pharma for its internal R & D and Hybrigenics Services for its business, contact the sake of economies of scale through a branch, administrative and financial community. The central link between all activities Hybrigenics is a belief that science works for life.